Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 10,202 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (oral) Clear all
Completed Phase 2 Interventional Results available

Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

NCT00813098
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
LX1031 High Dose, LX1031 Low Dose, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Tucson, Arizona • Sherwood, Arkansas • Anaheim, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Sep 17, 2026, 6:21 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03827798
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients

NCT00082498
View directory record Official record
Conditions
HIV Infections
Interventions
SCH-D (vicriviroc), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
30
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure

NCT01544998
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Nesiritide, Tadalafil, Placebo, Saline load
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma

NCT01386632
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DCA (dichloroacetate), Placebo
Drug
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
Fargo, North Dakota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

NCT05587998
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Morphine, AZD4041, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

NCT00872898
View directory record Official record
Conditions
Autism
Interventions
Memantine - Extended Release (ER), Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant

NCT01928199
View directory record Official record
Conditions
Posttransplant Diabetes Mellitus
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

NCT02607865
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, sitagliptin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Tuscumbia, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

NCT01585181
View directory record Official record
Conditions
Cholera
Interventions
PXVX0200, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Lexington, Kentucky • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 3 Interventional

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

NCT01617200
View directory record Official record
Conditions
Schizophrenia
Interventions
Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort

NCT07336836
View directory record Official record
Conditions
Health Adult Subjects, Healthy Participants
Interventions
LathMized TM NAD+ (LNAD+), Control (placebo)
Dietary Supplement · Other
Lead sponsor
BioNADrx Holdings, Inc. Bryleos
Industry
Eligibility
45 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Erosion Study to Investigate the Efficacy of an Experimental Dentifrice to Remineralize Enamel

NCT06242444
View directory record Official record
Conditions
Tooth Erosion
Interventions
Experimental Dentifrice, Placebo Control Dentifrice, Reference Dentifrice
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 17, 2026, 6:21 AM EDT
Terminated Phase 2 Interventional Results available

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

NCT03919799
View directory record Official record
Conditions
System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis
Interventions
Belumosudil (KD025), Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 100 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

NCT00295633
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
79
States / cities
Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 17, 2026, 6:21 AM EDT
Terminated Phase 1 Interventional

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

NCT01911325
View directory record Official record
Conditions
Squamous Non-small Cell Lung Cancer
Interventions
Buparlisib, Buparlisib matching placebo, Docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Fayetteville, Arkansas • Tampa, Florida • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 2Phase 3 Interventional

Acamprosate in the Treatment of Binge-Eating Disorder

NCT00511940
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
acamprosate, placebo
Drug · Other
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Sep 17, 2026, 6:21 AM EDT
Terminated Phase 3 Interventional Results available

Management Of Pain After Cesarean Trial

NCT03929640
View directory record Official record
Conditions
Pain, Postoperative, Opioid Use
Interventions
Acetaminophen, Placebo, Ibuprofen
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Setria Performance Blend Supplementation

NCT04090138
View directory record Official record
Conditions
Healthy
Interventions
Setria performance blend, Placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
20 Years to 30 Years · Male only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

NCT01757535
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Oral Azacitidine, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
55 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
60
States / cities
Phoenix, Arizona • Burbank, California • Duarte, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

NCT01125189
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 17, 2026, 6:21 AM EDT
Completed Not applicable Interventional

Functional Chewing Gum in Reduction of Gingival Inflammation

NCT03237624
View directory record Official record
Conditions
Gingivitis
Interventions
Functional Chitosan Chewing Gum, Control Chewing Gum, Oral hygiene measures
Device · Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 17, 2026, 6:21 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

NCT02907177
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ponesimod, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Birmingham, Alabama • Fresno, California • Pasadena, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 17, 2026, 6:21 AM EDT
Not listed Phase 2 Interventional

Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients

NCT01917630
View directory record Official record
Conditions
Celiac Disease
Interventions
ALV003, placebo
Drug
Lead sponsor
Alvine Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
79
States / cities
Decatur, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Sep 17, 2026, 6:21 AM EDT